Autoren: Gansevoort R, van Gastel M, Chapman A, Blais J, Czerwiec F, Higashihara E, Lee J, Ouyang J, Perrone R, Stade K, Torres V, and Devuyst O
Source: https://doi.org/10.1016/j.kint.2018.11.044
Indication: Nephrology
Product: Copeptin

In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
https://www.kidney-international.org/article/S0085-2538(19)30041-9/abstract >

Autoren: Tasneem M, Mannix C, Wong A, Zhang J and Rangan G
Source: World J Nephrol 2018;7 (2),Mar 6: 51-57
Indication: Nephrology
Access: Open Access
Product: Copeptin

Copeptin (the C-terminal glycoprotein of the precursor AVP peptide) is an accurate surrogate marker of AVP release that is stable and easily measured by immunoassay. Cohort studies show that serum copeptin is correlated with disease severity in ADPKD, and predicts future renal events [decline in renal function and increase in total kidney volume (TKV)].
https://www.ncbi.nlm.nih.gov/pubmed/29527508 >

Autoren: Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Cuerden MS, Weir MA, Bagga A, Brimble S, Burke A, Muirhead N, Pandeya S and Garg AX
Source: JAMA 2018;319 (18),May 8: 1870-1879.
Indication: Nephrology
Product: Copeptin

Among adults with chronic kidney disease, coaching to increase water intake compared with coaching to maintain the same water intake did not significantly slow the decline in kidney function after 1 year. However, the study may have been underpowered to detect a clinically important difference.
https://www.ncbi.nlm.nih.gov/pubmed/29801012 >